Dr. Reddy's Laboratories Limited Market Cap ($9.23 Billion)
Market Cap & Net Worth: Dr. Reddy's Laboratories Limited (RDDA)
Dr. Reddy's Laboratories Limited market cap. Dr. Reddy's Laboratories Limited (F:RDDA) has a market capitalization of $9.23 Billion (€7.89 Billion) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #2316 globally and #484 in its home market, demonstrating a 6.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dr. Reddy's Laboratories Limited's stock price €12.50 by its total outstanding shares 832594805 (832.59 Million).
Dr. Reddy's Laboratories Limited Market Cap History (2015–2026)
Dr. Reddy's Laboratories Limited market cap history from 2015 to 2026. Data shows growth from $5.53 Billion to $12.17 Billion (4.76% CAGR). Check RDDA stock price and chart for real-time trading data and today's change.
Dr. Reddy's Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dr. Reddy's Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see RDDA cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.04x
Dr. Reddy's Laboratories Limited's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.20x
Dr. Reddy's Laboratories Limited's market cap is 0.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $4.20 Billion | $140.81 Billion | $12.04 Billion | 0.03x | 0.35x |
| 2018 | $4.68 Billion | $142.03 Billion | $9.81 Billion | 0.03x | 0.48x |
| 2019 | $5.42 Billion | $153.85 Billion | $18.80 Billion | 0.04x | 0.29x |
| 2020 | $8.80 Billion | $174.60 Billion | $19.50 Billion | 0.05x | 0.45x |
| 2021 | $9.31 Billion | $189.72 Billion | $19.15 Billion | 0.05x | 0.49x |
| 2022 | $8.33 Billion | $214.39 Billion | $23.57 Billion | 0.04x | 0.35x |
| 2023 | $11.59 Billion | $245.88 Billion | $45.07 Billion | 0.05x | 0.26x |
| 2024 | $14.60 Billion | $279.16 Billion | $55.68 Billion | 0.05x | 0.26x |
| 2025 | $11.49 Billion | $325.54 Billion | $56.54 Billion | 0.04x | 0.20x |
Competitor Companies of RDDA by Market Capitalization
Companies near Dr. Reddy's Laboratories Limited in the global market cap rankings as of October 31, 2026. See RDDA net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Dr. Reddy's Laboratories Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Dr. Reddy's Laboratories Limited (2015–2026)
Market capitalization of Dr. Reddy's Laboratories Limited from 2015 to today. Between 2015 and today, Dr. Reddy's Laboratories Limited's market cap moved from $5.53 Billion to $ 12.17 Billion, with a yearly change of 4.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.17 Billion | +5.93% |
| 2025 | €11.49 Billion | -21.33% |
| 2024 | €14.60 Billion | +25.97% |
| 2023 | €11.59 Billion | +39.14% |
| 2022 | €8.33 Billion | -10.52% |
| 2021 | €9.31 Billion | +5.77% |
| 2020 | €8.80 Billion | +62.51% |
| 2019 | €5.42 Billion | +15.67% |
| 2018 | €4.68 Billion | +11.46% |
| 2017 | €4.20 Billion | -23.31% |
| 2016 | €5.48 Billion | -0.88% |
| 2015 | €5.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Dr. Reddy's Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.23 Billion USD |
| MoneyControl | $9.23 Billion USD |
| MarketWatch | $9.23 Billion USD |
| marketcap.company | $9.23 Billion USD |
| Reuters | $9.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more